Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 6:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Urothelial Carcinoma
Interventions
Pembrolizumab, Atezolizumab, Durvalumab, Nivolumab, Avelumab
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Empowering Cardiovascular Health in Custodial Grandparents

NCT07083895
Conditions
Cardiovascular Disease (CVD) Risk Factors
Interventions
Modified RICHH, Standard of Care (SOC)
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip, Avascular Necrosis, Rheumatoid Arthritis
Interventions
POPOP (preoperative patient optimization program), SOC (standard of care)
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma Refractory, Primary Mediastinal Large B-Cell Lymphoma Recurrent, Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Interventions
Pembrolizumab, Lymphodepletion Chemotherapy, Chimeric Antigen Receptor (CAR) Therapy Infusion, Leukapheresis
Drug · Procedure
Lead sponsor
Jennifer Crombie, MD
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Completed Not applicable Interventional Accepts healthy volunteers

Intervention to Enhance PrEP Uptake and Adherence in a Community-Based Setting

NCT02037594
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
Sexual Health Counseling, Enhanced Adherence Intervention, PrEP Information (Active Control), Standard of Care Adherence Support (Active Control)
Behavioral
Lead sponsor
Hunter College of City University of New York
Other
Eligibility
18 Years and older · Male only
Enrollment
438 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
Gastroesophageal Reflux
Interventions
Cognitive Behavioral Therapy, Sham-SOC Lifestyle Coaching
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • St Louis, Missouri
Conditions
Substance-related Disorders
Interventions
On-site bundled rapid HIV/HCV testing, Standard of care (SOC)
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Conditions
HIV Infection
Interventions
Linkage-to-Care Component: Financial Incentive (FI), Linkage-to-Care Component: Standard of Care (SOC), Viral Suppression Component: FI, Viral Suppression Component: SOC, Prevention for Positives Component: Counseling and SOC, Prevention for Positives Component: SOC
Behavioral
Lead sponsor
HIV Prevention Trials Network
Network
Eligibility
Not listed
Enrollment
18,442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Completed Not applicable Interventional Results available

Computer-based Intervention for Alcohol-using HIV/HCV+ Women

NCT03362476
Conditions
Human Immunodeficiency Virus, Hepatitis C, Alcohol Abuse
Interventions
Computer-based alcohol reduction intervention, Brief clinician-delivered MET, Standard of care
Behavioral
Lead sponsor
New York University
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
New York, New York
Conditions
Diabetic Foot Ulcers (DFUs), Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer)
Interventions
Miro3D Wound Matrix, Standard of Care (SOC)
Device · Other
Lead sponsor
Reprise Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Coconut Creek, Florida • Tamarac, Florida • New York, New York
Conditions
Kidney Transplant Recipients, Liver Transplant Recipients
Interventions
Pfizer-BioNTech COVID-19 Vaccine 2023-2024, Moderna COVID-19 Vaccine 2023-2024, SOC IS Regimen, SOC IS Reduction
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
15
States / cities
San Diego, California • San Francisco, California • Atlanta, Georgia + 10 more
Conditions
Corneal Edema, Corneal Defect, Anterior Chamber Inflammation, Ocular Pain, Corneal Staining, Visual Outcome, CME - Cystoid Macular Edema
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp, Prolensa 0.07% Ophthalmic Solution
Drug
Lead sponsor
Nicole Fram M.D.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Completed Phase 4 Interventional Results available

Belatacept 3 Month Post Transplant Conversion Study

NCT02213068
Conditions
Transplant; Failure, Kidney, EBV
Interventions
belatacept, Tacrolimus, MPA
Drug
Lead sponsor
Lorenzo Gallon
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS), Glioblastoma
Interventions
AL58805, AL3818, Temozolomide (TMZ), CCNU
Drug
Lead sponsor
Advenchen Pharmaceuticals, LLC.
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Conditions
Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis), Platelet Aggregation Inhibitors, Thromboelastography (TEG), PRU(Platelet Reactivity Unit)
Interventions
Aspirin, Clopidogrel, Ticagrelor, Rivaroxaban, Thromboelastography with Platelet Mapping
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Salem, Massachusetts
Conditions
Surgical Wound, Burns, Trauma Injury
Interventions
SupraSDRM®, NovoSorb® BTM
Device
Lead sponsor
The Metis Foundation
Other
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Conditions
COVID-19 Pneumonia
Interventions
PF-06650833, Matching Placebo
Drug
Lead sponsor
Giovanni Franchin, M.D, Ph.D
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Kidney Transplantation
Interventions
Arm 1: SOC (mTOR + CNI), Arm 2A: TRACT/MONO mTOR, Arm 2B: TRACT/MONO CNI
Drug · Biological
Lead sponsor
Singulera Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
Phoenix, Arizona • Chicago, Illinois • Rochester, Minnesota
Conditions
Sickle Cell Disease
Interventions
L-citrulline, Placebo
Drug · Other
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
6 Years to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Coral Gables, Florida • Atlanta, Georgia + 3 more
Conditions
Open-angle Glaucoma (OAG), Ocular Hypertension (OHT)
Interventions
Direct Selective laser Trabeculoplasty
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Recruiting Not applicable Interventional Accepts healthy volunteers

Rise With Resilience

NCT07217275
Conditions
Athletic Injuries, Sport Injuries
Interventions
Community Resiliency Model (CRM), Control
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 26 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides
Interventions
Biodynamic imaging (BDI) of mycosis fungoides
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee
Interventions
TRL1068 (calpurbatug), a human monoclonal antibody, DAIR
Drug · Procedure
Lead sponsor
Trellis Bioscience LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
11
States / cities
Gilbert, Arizona • Los Angeles, California • Jacksonville, Florida + 8 more
Conditions
Diabetic Foot Ulcer
Interventions
OptiPulse™, Standard of Care offloading device
Device
Lead sponsor
Compedica Inc
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
18
States / cities
Phoenix, Arizona • Los Angeles, California • Vista, California + 12 more